Topics in this section

Hepatitis and HIV: latest news

Hepatitis and HIV resources

  • The liver

    The liver plays an important role in how the body processes anti-HIV drugs.Hepatitis means inflammation of the liver and is relatively common in people with...

    From: Factsheets

    Information level Level 2
  • Hepatitis and other liver disease

    The liver has many important functions in the body. For people with HIV, it plays a vital role in processing the drugs used to treat HIV. Some...

    From: Booklets

    Information level Level 2
  • Hepatitis B

    The majority of people with hepatitis B do not have any symptoms.It is recommended that people living with HIV are tested and vaccinated for hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Liver function tests

    People living with HIV should have regular blood tests to monitor liver function.The liver plays an important role in processing drugs used to treat HIV...

    From: Factsheets

    Information level Level 2
  • Managing advanced liver disease

    Over years or decades, chronic hepatitis B or C can cause serious liver disease including advanced fibrosis, cirrhosis or liver cancer (hepatocellular cancer). As scar tissue or tumours...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • HIV & hepatitis

    This booklet gives information for people with HIV who also have hepatitis A, hepatitis B or hepatitis C....

    From: Booklets

    Information level Level 2
  • HIV and hepatitis co-infection

    Hepatitis is a viral infection that affects your liver. Some types – hepatitis B and C – can cause long-term, serious health problems. Many people with HIV...

    From: Booklets

    Information level Level 2
  • Non-HIV-related illnesses – hepatitis

    ‘Hepatitis’ means inflammation of the liver. The liver is the largest internal organ in your body. It is located at the upper right-hand side of the abdomen....

    From: Living with HIV

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • How hepatitis C is passed on

    When the blood of a person who has hepatitis C enters the bloodstream of another person, that person could get hepatitis C.Tiny and unseen traces...

    From: The basics

    Information level Level 1
  • How hepatitis C is passed on during sex

    Hepatitis C can be passed on during sex that could lead to contact with small traces of blood.Many gay men with HIV have picked up...

    From: The basics

    Information level Level 1
  • Other tests

    Blood pressure is the force that the beating heart causes in the arteries, veins, and blood vessels that carry blood around the body. Blood pressure is measured...

    From: Booklets

    Information level Level 2

Hepatitis and HIV features

Hepatitis and HIV in your own words

Hepatitis and HIV news from aidsmap

More news

Hepatitis and HIV news selected from other sources

  • Hepatitis C Sheds Enough in the Rectum to Transmit Through Anal Sex

    Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit directly to another man’s penis during anal sex, even when no blood is present.

    30 November 2016 | Poz
  • DAA treatment restricted for Canadian hepatitis C patients

    Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.

    29 November 2016 | Medical Economics
  • Decriminalization is a public health strategy

    We can’t end the viral hepatitis epidemics unless we end the war on drug users.

    18 October 2016 | Treatment Action Group
  • HCV Drugs May Reactivate HBV, FDA Warns

    Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

    06 October 2016 | Medscape (free registration required)
  • Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

    The e-poster presented at EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure reports that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).

    26 September 2016 | Achillion press release
  • The Lancet: Mass imprisonment of drug users driving global epidemics of HIV, hepatitis, and tuberculosis

    The War on Drugs, mass incarceration of drug users, and the failure to provide proven harm reduction and treatment strategies has led to high levels of HIV, tuberculosis, and hepatitis B and C infection among prisoners--far higher than in the general population. With an estimated 30 million people passing in and out of prisons every year, prisoners will be key to controlling HIV and tuberculosis epidemics worldwide, according to a major six-part Series on HIV and related infections in prisoners, published in The Lancet and being presented at the International AIDS Conference in Durban, South Africa.

    17 July 2016 | EurekAlert
  • Fast Advance in Hepatitis C Care Prompts EMA to Revise Clinical Trial Guideline

    EMA has proposed changes to its guideline on clinical trials of direct acting antiviral hepatitis C drugs. The revisions are intended to ensure the guideline reflects the dramatic changes that have happened in the hepatitis C sector since Gilead introduced its blockbuster Sovaldi (sofosbuvir).

    17 July 2016 | Regulatory Affairs Professionals Society
  • Viral hepatitis 'kills as many as Aids or TB'

    Viral hepatitis is one of the leading causes of death and disability across the globe, killing as many people as Aids or TB, research published in the Lancet suggests.

    07 July 2016 | BBC Health
  • HIV-to-HIV Organ Transplants Moving Forward

    Multicenter study preparing for launch, pilot studies already begun

    04 July 2016 | MedPage Today
  • FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes

    On June 28 the U.S. Food and Drug Administration (FDA) approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes 1 through 6 -- the first approved oral pangenotypic regimen. While it is more effective against more types of HCV, Epclusa will cost less than most earlier interferon-free direct-acting antiviral regimens.

    04 July 2016 | HIVandHepatitis.com
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.